Clinical trials: Genital Infection
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months and 0,12 months) in healthy 9-14 year old…
- Trial name
- NCT01381575
- Testing
- GSK Biologicals' HPV vaccine 580299
- Where
- 33 sites in Canada, Germany and 3 more
- Volunteers
- 1,447 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
- Trial name
- NCT00002266
- Testing
- AS-101
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir
To evaluate the safety and efficacy of foscarnet induction treatment of cytomegalovirus (CMV) retinitis in AIDS patients who have previously suffered severe dose-limiting ganciclovir-related myelosuppression, who are ineligible…
- Trial name
- NCT00002301
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
HIV Infections, Cytopenias
The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT
To determine the safety and efficacy of erythropoietin administered subcutaneously to AIDS patients with anemia secondary to their disease and/or concomitant zidovudine (AZT) therapy.
- Trial name
- NCT00002302
- Testing
- Epoetin alfa
- Where
- 2 sites in United States
- Sponsor
- Ortho Pharmaceuticals
AIDS, HIV Infections
Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers
GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or…
- Trial name
- NCT00434512
- Testing
- HIV vaccine 732461
- Where
- Belgium
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pelvic Inflammatory Disease
Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.
Comparison of various antibiotics in treatment of uncomplicated pelvic inflammatory disease
- Trial name
- MAIDEN (NCT00683865)
- Testing
- Ofloxacin, Avelox (Moxifloxacin, BAY12-8039)
- Where
- 77 sites in Denmark, Finland and 11 more
- Volunteers
- 749 people
- Sponsor
- Bayer
HIV Infection
An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
The objective of the study is to compare two doses of MVA-nef vs. MVA-BN to induce Nef-specific cellular immune response in HIV-1 infected patients
- Trial name
- NCT00189930
- Testing
- MVA-nef, IMVAMUNE
- Where
- 5 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Bavarian Nordic
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Human Papillomavirus Infection
Phase I Clinical Trial of a Candidate HPV Vaccine
This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.
- Trial name
- NCT05672966
- Testing
- Human papillomavirus (HPV) Vaccine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
HIV Infections
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
This is an active control, randomized study to investigate the safety, tolerability and PK of repeat dose administration of long-acting CAB 400 mg/mL formulation intramuscular (IM) (gluteus medius and vastus lateralis) and…
- Trial name
- NCT04484337
- Testing
- Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies.
- Trial name
- VOLITION (NCT05917509)
- Testing
- DTG/3TC, Cabotegravir (CAB) LA, Rilpivirine (RPV) LA
- Where
- 47 sites in United States, Argentina and 7 more
- Volunteers
- 171 people
- Sponsor
- ViiV Healthcare
HPV Infection, HPV-Related Cervical Carcinoma
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group.
- Trial name
- NCT04436133
- Testing
- Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), 9-valent HPV vaccine（Gardasil 9）
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
HIV Infections
Drug Exposure Registry for GSK2248761, an Investigational NNRTI
The World Health Organization has estimated that as many as 10% of the population worldwide may at some point experience at least one seizure. The percentage with active epilepsy is from 0.4% to 1%.
- Trial name
- NCT01458132
- Volunteers
- 19 people
- Sponsor
- ViiV Healthcare
HIV Infections
Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients
To determine the tolerance and side effects of a combination of lentinan and didanosine (ddI) compared with ddI alone. To determine whether the combination of lentinan and ddI produces a significant immunorestorative effect…
- Trial name
- NCT00002098
- Testing
- Lentinan, Didanosine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- AJI Pharma USA
HIV Infections
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
This study will evaluate T-20 in children.
- Trial name
- NCT00022763
- Testing
- Enfuvirtide
- Where
- 7 sites in United States
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors
The purpose of this study is to determine the safety and tolerability of the study drug DPC 083 combined with 2 nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected patients who are failing their nonnucleoside…
- Trial name
- NCT00007449
- Testing
- DPC 083
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dupont Applied Biosciences
HIV Infections
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
To determine the safety and tolerance of various combinations of zidovudine (AZT) and didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent AZT and ddI administered orally.
- Trial name
- NCT00002014
- Testing
- Zidovudine, Didanosine
- Where
- 4 sites in United States
- Sponsor
- Glaxo Wellcome
Acquired Immune Deficiency Syndrome
A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence
The purpose of this study is to assess the safety data of etravirine in a natural clinical practice.
- Trial name
- NCT01741844
- Testing
- No intervention
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Janssen Korea, Ltd., Korea
Vaginal Infection
Multi-Center Study of New Medications to Treat Vaginal Infections
The purpose of this study is to evaluate the safety and efficacy of metronidazole gel in the treatment of vaginal infections.
- Trial name
- SMART GIVES (NCT02308033)
- Testing
- Metronidazole, Gel vehicle
- Where
- 35 sites in United States
- Volunteers
- 204 people
- Sponsor
- Curatek Pharmaceuticals, LLC
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.